Climb Bio Inc
CLYM1.950USD
+0.030+1.56%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
132.14MMarket Cap
LossP/E TTM
More Details of Climb Bio Inc Company
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
Climb Bio Inc Info
Ticker SymbolCLYM
Company nameClimb Bio Inc
IPO dateAug 10, 2021
CEODr. Aoife M. Brennan
Number of employees17
Security typeOrdinary Share
Fiscal year-endAug 10
Address20 William Street
CityWELLESLEY HILLS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02481
Phone18668572596
Websitehttps://climbbio.com/
Ticker SymbolCLYM
IPO dateAug 10, 2021
CEODr. Aoife M. Brennan
Company Executives of Climb Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Oct 18
Updated: Sat, Oct 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
46.37%
Pontifax Venture Capital
7.68%
Cantor Fitzgerald, L.P
3.69%
Citi Investment Research (US)
2.38%
Affinity Asset Advisors LLC
2.21%
Other
37.67%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
46.37%
Pontifax Venture Capital
7.68%
Cantor Fitzgerald, L.P
3.69%
Citi Investment Research (US)
2.38%
Affinity Asset Advisors LLC
2.21%
Other
37.67%
Shareholder Types
Shareholders
Proportion
Venture Capital
54.05%
Hedge Fund
12.08%
Investment Advisor
11.01%
Research Firm
3.33%
Investment Advisor/Hedge Fund
1.18%
Individual Investor
0.81%
Other
17.54%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
175
55.33M
81.65%
-9.92M
2025Q2
169
62.56M
92.58%
-4.83M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
31.42M
46.37%
--
--
Jun 30, 2025
Pontifax Venture Capital
5.21M
7.68%
+5.21M
--
Mar 31, 2025
Cantor Fitzgerald, L.P
2.50M
3.69%
+503.12K
+25.16%
Jun 30, 2025
Citi Investment Research (US)
1.61M
2.38%
-238.23K
-12.88%
Jun 30, 2025
Affinity Asset Advisors LLC
1.50M
2.21%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.33M
1.96%
-171.31K
-11.40%
Jun 30, 2025
Deep Track Capital LP
1.04M
1.53%
--
--
Jun 30, 2025
Kynam Capital Management LP
1.03M
1.52%
-18.66K
-1.78%
Jun 30, 2025
Tang Capital Management, LLC
1.00M
1.48%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
829.63K
1.22%
-1.27M
-60.45%
Jun 30, 2025
View more
Related ETFs
Updated: 19 hours ago
Updated: 19 hours ago
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
